高效生成人类 cDC1 样细胞，通过 CD4(+) T 细胞辅助来检测并增强肿瘤反应性 T 细胞

Classical type 1 dendritic cells (cDC1s) are crucial to anti-tumor immunity by cross-presenting tumor antigens and priming cytotoxic CD8 + T lymphocytes (CTLs). Licensing via CD4 + T cell help endows cDC1s with enhanced cross-presentation and CTL-priming capacity, making them a promising tool to improve adoptive T cell therapies.

However, the scarcity of primary human cDC1s limits their in-depth translational investigation and application.

Here, we describe a method to efficiently generate DCs in vitro from CD34 + c-KIT + progenitors in non-mobilized peripheral blood. This DC population is enriched for cDC1-like cells that respond to CD4 + T cell help by upregulation of key molecules involved in antigen cross-presentation and T cell costimulation.

Upon CD4 + T cell-mediated licensing, the progenitor-derived DC promotes tumor-specific CTL priming and facilitates detection of rare tumor antigen-specific CD8 + T cells in blood and tumor tissues. This DC culture platform incorporating CD4 + T cell help provides a scalable system for immunomonitoring and optimizing adoptive T cell therapies in cancer.